Company Overview and News
Amazon (AMZN - Free Report) may be rapidly gaining digital advertising market share, but it also has a comprehensive physical store expansion up its sleeve. So despite the valuation, analysts continue to raise their price targets-
WFCNP FB AT WMT LNSTY WFC EOG ATP GOOGL SRE MSFT SPG APRWF
2018-09-21 seekingalpha - 2
Huge dividend cuts during 2008-2009 combined with unstable dividend payments are causes for concern for dividend-seeking investors.
VIG WFCNP PM MTSI PG XOM ABT WMT VZA CSCO KO VYM INTC MCD MMM ABT WFC UNP MDT T JNJ CVX VZ MSFT PFE
2018-09-21 zacks - 1
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), EOG Resources (EOG) and Simon Property Group (SPG). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP TXN NFLX MS WFC UNP EOG S SPG
Over the last five trading days, major banks’ rally continued on expectation of interest rate hike this month. The rate hike will translate into top-line expansion for banks, leading to improved results in the quarters ahead. Further, given the growth in economy, low unemployment rate and healthy consumer sentiment, the demand for loans and other related products of banks are expected to rise. However, imposition of tariffs on $200 billion worth of Chinese goods next week could escalate trade war tensions, impacting consumers and increasing inflation.
WFCNP FITBI BAC USB WFC BAC C MBFI UTX MBFIP EOG FITB
2018-09-21 247wallst - 3
Stocks were indicated marginally higher on Friday, but this as after the Dow Jones industrials and S&P 500 hit all-time high closes on Thursday. International markets were also higher on Friday, but many international and emerging markets are still very far away from their all-time highs. As many investors have seen lower upside from buying on market pullbacks than in prior years, they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
WFCNP CPRT UAA FSCT DRI AMD ETN NVAX AYI.WI AAI EDIT ASUV AA WFC AYI NBEV DO ACAD UA ABRW T TRI HLIT
Micron Technology– Micron reported adjusted quarterly profit of $3.53 per share, beating the consensus estimate of $3.34 a share. The chipmaker's revenue also topped forecasts, however the stock erased an initial gain after company executives said U.S. tariffs on China goods would impact its financial results for as much as one year.
WFCNP TXN UAA ADBE AYI.WI DAL MZOR WFC AYI UNFI UA MU
Chicago, IL – September 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wells Fargo (WFC - Free Report) , Schlumberger (SLB - Free Report) , Biogen (BIIB - Free Report) , American Express (AXP - Free Report) and Illinois Tool Works (ITW - Free Report) .
WFCNP CY LB GIII BIIB WIFI VSH NCLH WFC SLB REGN ON CSBR BSTC ITW SLB
Wells Fargo & Company’s (WFC - Free Report) CEO Tim Sloan, in a bi-monthly meeting held on Thursday, said that the company plans to reduce its workforce by 5-10% in the next three years, as it seeks to transform itself into a more efficient and customer-oriented firm.
WFC WFCNP CMA CMPWW USB BK
A lawsuit is filed against The Goldman Sachs Group (GS - Free Report) by two brokerage firms — The Charles Schwab Corporation (SCHW - Free Report) and TD Ameritrade Holding Corporation (AMTD - Free Report) — over a 17-year old stock-sharing agreement, per an article by Reuters.
WFCNP GS GLSSP AMTD WFC JBK GSC TFG GSJ GJS
U.S. stock-index futures inched higher on Friday, indicating that Wall Street would extend its recent uptrend and push further into record levels.
WFC WFCNP GOOG ADBE GOOGL MU MZOR
(Sep 21): Wells Fargo & Co said on Thursday it would reduce its headcount by about 5 percent to 10 percent within the next three years as part of a turnaround plan.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET